

המרכז לחקר הביולוגיה של הסרטן • הפקולטה לרפואה ע"ש סאקלר • הפקולטה למדעי החיים ע"ש ג'ורג' ס' וייז
CANCER BIOLOGY RESEARCH CENTER • SACKLER FACULTY OF MEDICINE • GEORGE S. WISE FACULTY OF LIFE SCIENCES

TEL AVIV UNIVERSITY  אוניברסיטת תל-אביב

CANCER BIOLOGY RESEARCH CENTER

GEORGE S. WISE FACULTY OF LIFE SCIENCES

SACKLER FACULTY OF MEDICINE

**2013 BIENNIAL RETREAT OF THE
CANCER BIOLOGY RESEARCH CENTER**

**June 19-22, 2013
Canaan Spa Hotel, Safed**

CD38 DEFICIENCY ATTENUATES MELANOMA PROGRESSION

E. Blacher¹, N. Geva¹, L. Mayo², R. Stein¹

¹Dept. of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel, ²Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (L.M.), USA

GROWTH OF POORLY DIFFERENTIATED ENDOMETRIAL CARCINOMA IS INHIBITED BY COMBINED ACTION OF MEDROXYPROGESTERONE ACETATE AND THE RAS INHIBITOR SALIRASIB

R. Faigenbaum¹, R. Haklai¹, G. Ben-Baruch², Y. Kloog¹

¹Dept of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, ²Dept of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Israel

THE ROLE OF TEL-TIF2 IN ACUTE LEUKEMIA WITH COMBINED MYELOID AND T-CELL PHENOTYPE

H. Fishman^{1,2}, Y. Kirschenbaum^{1,2}, I. Ganmore^{1,2}, Y. Birger¹, S. Izraeli^{1,2}

¹Institute of Childhood Leukemia Research, Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer, ²Dept. of Human Molecular Genetics and Biochemistry, Tel Aviv University, Israel

ADAR1 REGULATES THE RESISTANCE OF MELANOMA CELLS TO T-CELLS VIA MIR-222 AND ICAM1

G. Galore-Haskel^{1,2}, Y. Wolff-Nemlich^{1,2}, E. Greenberg^{1,2}, M. Gutman³, M.J. Besser^{1,2}, J. Schachter², G. Markel^{1,2,4}

¹Dept. of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, ²Ella Institute of Melanoma, Chaim Sheba Medical Center, Tel Hashomer, Israel, ³Dept. of General Surgery (Surgery B), Chaim Sheba Medical Center, Tel Hashomer ⁴Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Tel Hashomer, Israel

SAME CLUSTER MicroRNA -17 AND-20A DIFFERENTIAL REGULATION OF AGGRESSIVE FEATURES IN MELANOMA CELLS

E. Greenberg^{1,2}, S. Hajdu¹, Y. Nemlich^{1,2}, R. Cohen^{1,2}, R. Ortenberg^{1,2}, O. Itzhaki¹, J. Jacob³, M. Besser^{1,2}, Y. Keisari², J. Schachter¹, G. Markel^{1,2,4}

¹Ella Institute of Melanoma, Chaim Sheba Medical Center, Tel Hashomer, ²Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, ³Cancer Biology Research Center, ⁴Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Tel Hashomer, Israel

CHEMOKINE AND CELLULAR MOTIFS REGULATING THE SECRETION OF CCL2: POTENTIAL POINTS FOR INTERVENTION IN PRO-MALIGNANCY ACTIVITIES IN BREAST CANCER

Y. Lebel-Haziv¹, T. Meshel¹, A. Yeheskel², E. Mamon¹, A. Ben-Baruch¹

¹Dept. of Cell Research and Immunology, ²Bioinformatics Unit, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel

MICROMETASTASIS REGULATION BY THE LUNG MICROENVIRONMENT IN NEUROBLASTOMA

S. Maman^{1,2}, L. Edry-Botzer¹, O. Sagi-Assif¹, T. Meshel¹, W. Yuan², W. Lu², I.P. Witz^{1,2}

¹Dept. of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel, ²Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA

MicroRNA-MEDIATED LOSS OF ADAR1 IN METASTATIC MELANOMA PROMOTES TUMOR GROWTH

Y. Nemlich^{1,6}, E. Greenberg^{1,7}, R. Ortenberg^{1,7}, M.J. Besser^{1,7}, I. Barshack², J. Jacob-Hirsch³, E. Jacoby^{3,4}, E. Eyal³, L. Rivkin¹², V.G. Prieto⁸, N. Chakravarti⁸, L.M. Duncan¹⁰, D.M. Kallenberg¹¹, E. Galun¹², D.C. Bennett¹¹, N. Amariglio³, M. Bar-Eli⁹, J. Schachter¹, G. Rechavi^{3,6}, G. Markel^{1,5,7}

¹Ella Institute of Melanoma, ²Institute of Pathology, ³Cancer Biology Research Center, ⁴Dept. of Pediatric Hemato-oncology, ⁵Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Tel Hashomer, Israel, ⁶Human Genetics and Biochemistry, ⁷Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Israel, ⁸Pathology, ⁹Cancer Biology, MD Anderson Cancer Center, Houston, TX, USA, ¹⁰Massachusetts General Hospital Dermatopathology Unit, Boston, MA, USA, ¹¹Biomedical Science Research Centre, St. George's, University of London, UK, ¹²Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel

ENHANCED ADHESION & MIGRATION AND INDUCTION OF PYK2 EXPRESSION IN K562 CELLS FOLLOWING IMATINIB EXPOSURE

A. Ovcharenko^{1,4}, G. Granot^{1,4}, J. Park², O. Shpilberg^{1,3,4}, P. Raanani^{1,3,4}

¹Felsenstein Medical Research Center, Beilinson Hospital, Petah Tikva, Israel, ²Massachusetts Institute of Technology, Cambridge, MA, USA, ³Institute of Hematology, Beilinson Hospital, Petah Tikva, ⁴Sackler School of Medicine, Tel Aviv University, Israel

THE ROLE OF MicroRNAs IN ACUTE MEGAKARYOCYTIC LEUKEMIA OF CHILDREN WITH DOWN SYNDROME

L. Shaham^{1,2}, G. Yubin⁴, E. Greenberg^{1,3}, G. Markel^{1,3}, M. Ginzburg¹, E. Eyal¹, Y. Spector⁵, J. Taub⁴, S. Izraeli^{1,3}

¹Chaim Sheba Medical Center, Tel Hashomer, ²The Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, ³Faculty of Medicine, Tel Aviv University, Israel, ⁴Children's Hospital of Michigan, Detroit, MI, USA, ⁵Rosetta Genomics, Rehovot, Israel

FROM MURINE TO HUMANIZED, BIG AND SMALL, UNARMED AND CONJUGATED: NOVEL AND PROMISING BIOLOGICAL TREATMENT TOOLS FOR CD24-EXPRESSING MALIGNANCIES

S. Shapira¹, D. Kazanov¹, I. Benhar³, N. Arber¹, S. Kraus¹

¹The Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center, ²The Sackler Faculty of Medicine, ³Dept of Molecular Microbiology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel

AMPK-MEDIATED REVERSAL OF THE METABOLIC SWITCH BY GLUCAGON-LIKE PEPTIDE 1: A NOVEL INTERACTION BETWEEN DIABETES AND BREAST CANCER

H. Ligumsky^{1,2}, **T. Rubinstein**^{1,2}, T. Scherf³, A. Karasik⁴, T. Rubinek¹, I. Wolf^{1,2}

¹Institute of Oncology, Tel Aviv Sourasky Medical Center, ²Sackler Faculty of Medicine, Tel Aviv University, ³Weizmann Institute of Science, Rehovot, ⁴Endocrinology Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel

THE METASTATIC MICROENVIRONMENT. FUNCTIONAL GENOMICS OF VEMURAFENIB-RESISTANT MELANOMA CELLS

I. Zubrilov¹, O. Sagi-Assif¹, S. Izraeli¹, A. Klein-Goldberg¹, T. Meshel¹, S. Ben-Menachem¹, D.S.B. Hoon², I.P. Witz¹

¹Dept. of Cell Research and Immunology, Faculty of Life Sciences, Tel Aviv University, Israel, ²John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, CA, USA

Wednesday, June 19, 2013 (cont'd)

16:00 Break, Poster Viewing and Visit the Exhibition

16:20-18:25

Session II - Prevention

Alon Hall

Chairs: **A. Sella**
J. Nordenberg

- 16:20 LESSONS FROM THE BIOLOGY OF OVARIAN CANCER ON THE PROSPECTS FOR EARLY DIAGNOSIS AND PREVENTION
K. Bahar-Shany¹, H. Brand¹, S. Sapoznik¹, J. Korach², G. Ben Baruch², R. Frommer-Shapira³, J. Jacob-Hirsch¹, Y. Cohen⁴, A. Hourvitz⁵, **K. Levanon**^{1,3}
¹Sheba Cancer Research Center, ²Dept. of Gynecologic Oncology, ³The Institute of Oncology, ⁴Sheba Institutional Tissue Bank, ⁵IVF Unit, Dept. of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Israel
- 16:35 BONE LOSS MEDIATED BY ERYTHROPOIETIN TREATMENT
S. Hiram-Bab¹, N. Deshet-Unger¹, M. Gross¹, M.C. Souroujon², Y. Gabet³, M. Mittelman⁴, D. Neumann¹
¹Dept. of Cell and Developmental Biology, Tel Aviv University, ²Dept. of Natural Sciences, The Open University of Israel, Raanana, ³Dept. of Anatomy, Tel Aviv University, ⁴Dept. of Medicine, Tel Aviv Sourasky Medical Center, Israel
- 16:45 HYALURONAN GRAFTED LIPID-BASED PARTICLE CLUSTERS IMPROVE THE THERAPEUTIC OUTCOME OF DOXORUBICIN IN HIGHLY RESISTANT OVARIAN CARCINOMA BY BYPASSING P-GP EFFLUX PUMPS
K. Cohen^{1,2}, R. Emmanuel^{1,2}, D. Peer^{1,2}
¹Dept. of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, ²Center for Nanoscience and Nanotechnology, Tel Aviv University, Israel
- 16:55 NEW STRATEGIES FOR EARLY DETECTION OF LUNG CANCER
Y. Schwarz
Dept. of Pulmonary Medicine, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv, Israel
- 17:10 THE RISE AND FALL OF PSA IN PROSTATE CANCER SCREENING
N.J. Majeesh
Dept. of Urology, Tel Aviv Sourasky Medical Center, Israel
- 17:25 DIFFERENT METHODS FOR SCREENING COLORECTAL CANCER
Y. Niv
Dept. of Gastroenterology, Rabin Medical Center, Petach Tikva, Tel Aviv University, Israel
- 17:40 MAMMOGRAPHY, ULTRASOUND OR MRI FOR EARLY DETECTION OF BREAST CANCER?
T. Karni
Dept. of Surgery, Assaf Harofeh Medical Center, Zerifin, Israel

Thursday, June 20, 2013

08:00-08:55

Breakfast and Meet the Expert

Parallel Session A

Alon Hall

HOW CAN I BEGIN MY RESEARCH?

D. Sidransky

Dept. of Otolaryngology and Oncology,
Johns Hopkins University, Baltimore, MD, USA

Parallel Session B

Rakefet Hall

HOW DO I WRITE MY FIRST GRANT?

Y. Kloog

Dept. of Neurobiology, George S. Wise Faculty of
Life Sciences, Tel Aviv University, Israel

Parallel Session C

Narkis Hall

HOW TO BECOME A PHYSICIAN SCIENTIST

G. Rechavi

Cancer Research Center, Chaim Sheba Medical Center,
Tel Hashomer, Sackler Faculty of Medicine,
Tel Aviv University, Israel

Parallel Session D

Calanit Hall

HOW TO DESIGN CLINICAL TRIALS FROM PHASE
1 TO PHASE 4

R. Berger

Institute of Medical Oncology, Sheba Cancer Research Center,
Chaim Sheba Medical Center, Tel Hashomer, Israel

Parallel Session E

Gal Hakahol Hall

USING PRECLINICAL MODELS TO GUIDE CLINICAL
CANCER TRIALS?

D. Hanahan

The Swiss Institute for Experimental Cancer Research
(ISREC), School of Life Sciences, Swiss Federal Institute of
Technology Lausanne (EPFL), Lausanne, Switzerland

08:55 Technical Break

Thursday, June 20, 2013 (cont'd)

09:00-09:50 **Session III - Nanomedicine** Alon Hall

Chairs: **Y. Keisari**
 L. Vardimon

- 09:00 GAGOMERS: A BIO-MATERIAL BASED DRUG DELIVERY TECHNOLOGY WITH CELL SPECIFIC TARGETING TO TUMORS
R. Margalit
Dept. of Biochemistry and Molecular Biology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel
- 09:20 MULTI-MODAL NANOMEDICINE FOR PERSONALIZED THERAPY OF GLIOBLASTOMA
P. Ofek¹, M. Calderon², F. Sheikhi-Mehrabadi², S. Ferber², R. Haag², R. Satchi-Fainaro¹
¹Dept. of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Israel, ²Organic and Macromolecular Chemistry, Dept. of Chemistry and Biochemistry, Free University of Berlin, Germany
- 09:30 INDUCING A DORMANT-LIKE STATE ON GLIOBLASTOMA USING A NANOMEDICINE BASED ON THE MOLECULAR FINGERPRINT OF TUMOR DORMANCY
S. Ferber¹, G. Tiram¹, O. Amsalem², N. Almog³, J. Henkin⁴, E. Yavin², R. Satchi-Fainaro¹
¹Dept. of Physiology and Pharmacology, Sackler School Medicine, Tel Aviv University, ²School Of Pharmacy Institute For Drug Research, Faculty of Medicine, The Hebrew University Of Jerusalem, Israel, ³Center Of Cancer Systems Biology, Caritas St. Elizabeth's Medical Center, Tufts University School Of Medicine Boston, MA, ⁴Chemistry Of Life Processes Institute, Northwestern University, Evanston, IL, USA
- 09:40 SWEET ENCOUNTERS WITH XENO-AUTOANTIBODIES
V. Padler-Karavani
Dept. of Cell Research & Immunology, Faculty of Life Sciences, Tel Aviv University, Israel

09:50-11:20 **Session IV - The RNA World** Alon Hall

Chairs: **Y. Kloog**
 M. Pasmanik-Chor

- 09:50 **Keynote Lecture**
RNA METHYLATION
G. Rechavi
Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Israel
- 10:20 MicroRNA - PROGNOSIS, DIAGNOSIS, SURVEILLANCE
N. Shomron
Faculty of Medicine, Tel Aviv University, Israel
- 10:40 MicroRNAs AND RNA EDITING ENZYMES IN MELANOMA
G. Markel
Ella Institute of Melanoma, Chaim Sheba Medical Center, Tel Hashomer, Israel

Thursday, June 20, 2013 (cont'd)

09:50-11:20 **Session IV - The RNA World (cont'd)** Alon Hall

- 11:00 INTERCELLULAR TRANSFER OF VIRAL MICRO RNAS CONTRIBUTES TO KAPOSÍ'S SARCOMA IMMUNE EVASION
N. Rainy^{1,2}, O. Rechavi¹, I. Goldstein², Y. Kloog¹
¹Dept. of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, ²Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Israel
- 11:10 THE EXPRESSION OF HSA-MIR-182 IN BREAST CANCER
A. Fokra
Sackler Faculty of Medicine, Tel Aviv University, Israel
- 11:20 Break, Poster Viewing and Visit the Exhibition

11:45-13:00 **Session IV - The RNA World (cont'd)** Alon Hall

- 11:45 ERG AS A DRIVER IN ACUTE MYELOID LEUKEMIA - AN INTEGRATIVE GENOMIC ANALYSIS OF A TRANSGENIC MOUSE MODEL
S. Izraeli
Chaim Sheba Medical Center, Tel Hashomer, Israel
- 12:05 INTERCELLULAR TRANSFER OF SMALL RNAS BETWEEN ASTROCYTES AND TUMOR CELLS
A. Menachem¹, M. Pasmanik-Chor², Y. Kloog¹
¹Dept. of Neurobiology, ²TAU Bioinformatics Unit, Life Sciences Faculty, Tel Aviv University, Israel
- 12:15 COMPREHENSIVE MOLECULAR PROFILING OF TUMOR EVOLUTION IN RECURRENT BREAST CANCER
M. Dadiani¹, N. Bossel⁵, T. Libbat¹, S. Kahana-Edwin¹, S. Paluch-Shimon², A. Pavlovski³, A. Yosepovich³, N. Epstein², E. Gal-Yam^{1,2}, I. Barshack^{3,4}, E. Domany⁵, B. Kaufman^{2,4}
¹Cancer Research Center, ²Oncology Institute, ³Pathology Institute, Chaim Sheba Medical Center, Tel Hashomer, ⁴Sackler Faculty of Medicine, Tel Aviv University, ⁵Weizmann Institute of Science, Rehovot, Israel
- 12:25 MIR-93 AND MIR-200C - NOVEL MOLECULAR REGULATORS OF TUMOR DORMANCY
G. Tiram¹, E. Segal¹, G. Bachar¹, R. Shreberk¹, S. Ferber¹, P. Ofek¹, T. Udagawa², L. Edry³, N. Shomron³, M. Roniger⁴, B. Kerem⁴, L. Benayoun⁵, Y. Shaked⁵, R. Satchi-Fainaro¹
¹Dept. of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Israel, ²Vascular Biology Program and Dept. of Surgery, Children's Hospital Boston and Harvard Medical School, Boston, MA, USA, ³Cell & Developmental Biology, Sackler School of Medicine, Tel Aviv University, Israel, ⁴Dept. of Genetics, The Life Sciences Institute, Edmond J. Safra Campus, The Hebrew University of Jerusalem, ⁵Dept. of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

Thursday, June 20, 2013 (cont'd)

11:45-13:00 **Session IV - The RNA World (cont'd)** Alon Hall

12:35 LONG NONCODING RNAs IN CANCER
I. Dotan, S. Tzadok, R. Aram, Y. Hachmo, Y. Caspin, **D. Canaani**
Dept. of Biochemistry and Molecular Biology, Faculty of Life Sciences,
Tel Aviv University, Israel

12:55 Panel Discussion

13:00 Lunch Break, Poster Viewing and Visit the Exhibition

13:10-14:00 **Lunch & Brain Storming Session**

Parallel Session A

Alon Hall

IS THERE A REAL BREAKTHROUGH IN THE THERAPY
OF BRAIN TUMORS?

Y. Kloog¹, Z. Ram²

¹Dept. of Neurobiology, George S. Wise Faculty of
Life Sciences, Tel Aviv University, ²Dept. of Neurosurgery,
Tel Aviv Sourasky Medical Center, Israel

Parallel Session B

Rakefet Hall

NOVELTIES IN BONE MARROW TRANSPLANTATION
AND IMMUNOTHERAPY OF CANCER

J. Schachter

Division of Oncology, Ella Institute for Melanoma,
Chaim Sheba Medical Center, Tel Hashomer, Israel

Parallel Session C

Narkis Hall

FUTURE CHALLENGES IN PEDIATRIC HEMATO-ONCOLOGY

I. Yaniv¹, P. Raanani²

¹Dept. of Pediatric Hematology & Oncology,
Schneider Children's Medical Center, Petach Tikva,
²Hemato-Oncology Hospitalization Unit, Institute of Hematology,
Davidoff Cancer Center, Beilinson Hospital - Rabin Medical Center,
Petach Tikva, Israel

Parallel Session D

Calanit Hall

CHALLENGES IN COMMERCIALIZATION OF
PHARMACEUTICAL TECHNOLOGIES

T. Raz

Ramot, Tel Aviv University, Israel

Parallel Session E

Gal Hakahol Hall

WHAT IS REAL PERSONALIZED MEDICINE TODAY?

I. Barshack¹, E. Friedman²

¹Dept. of Pathology, ²The Susanne Levy Gertner Oncogenetics
Unit, Danek Gertner Institute of Human Genetics, Chaim Sheba Medical
Center, Tel Hashomer, Israel

Thursday, June 20, 2013 (cont'd)

14:00-15:45	Session V - Pathogenesis - Inflammation, Infection and Cancer	Alon Hall
-------------	--	-----------

Chairs: **Y. Keisari**
Y. Skornick

- 14:00 IMMUNOMODULATORY AND METABOLIC EFFECTS OF ERYTHROPOIETIN - THE GOOD AND THE BAD?
N. Deshet-Unger¹, S. Hiram-Bab¹, Y. Ohana¹, M. Gross¹, Y. Gabet², H. Oster³, M. Mittelman³ **D. Neumann**¹
¹Dept. of Cell and Developmental Biology, ²Dept. of Anatomy, ³Dept. of Medicine, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel
- 14:20 LIVER INFLAMMATION LEADS TO THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA
O. Shibolet
Liver Unit, Dept. of Gastroenterology, Tel Aviv Sourasky Medical Center and Tel Aviv University, Israel
- 14:40 INFLAMMATORY BOWEL DISEASE AND CANCER AS THE PROTOTYPE MODEL FOR CANCER DRIVEN BY INFLAMMATION
I. Dotan
IBD Center, Dept. of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, Israel
- 15:00 ANGIOGENESIS AS A TARGET FOR ANTI-CANCER TREATMENT
B. Brenner
Davidoff Center, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Sackler Faculty of Medicine, Tel Aviv University, Israel
- 15:20 BURDEN AND PREVENTION OF CANCER OF INFECTIOUS ETIOLOGY
D. Cohen
School of Public Health and Stanley Steyer Institute for Cancer Epidemiology and Research, Sackler Faculty of Medicine, Tel Aviv University, Israel
- 15:35 Panel Discussion
- 15:45 Break, Poster Viewing and Visit the Exhibition

Thursday, June 20, 2013 (cont'd)

16:15-18:05 **Session VI - Everything You Always Wanted to Know About Omics and Cancer** Alon Hall

Chairs: **R. Geva**
 N. Shomron

- 16:15 **WHOLE EXOME SEQUENCE CAN IDENTIFY NEW ONCOGENES AND LOSS OF TSG**
E. Friedman
The Susanne Levy Gertner Oncogenetics Unit, Danek Gertner Institute of Human Genetics Chaim Sheba Medical Center, Tel Hashomer, Israel
- 16:30 **BRCA MUTATIONS AND OUTCOME IN EPITHELIAL OVARIAN CANCER (EOC): EXPERIENCE IN ETHNICALLY DIVERSE GROUPS**
T. Safra^{1,2}, W.C. Lai¹, L. Borgato³, M.O. Nicoletto³, T. Berman², E. Reich¹, M. Alvear¹, F.M. Muggia¹, I. Haviv^{4,5}
¹New York University Cancer Institute, New York, NY, USA, ²Dept. of Oncology, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Israel, ³Instituto Oncologico Veneto - IRCCS, Padova, Italy, ⁴Dept. of Pathology, School of Medicine, University of Melbourne, Parkville, Victoria, Australia; ⁵Faculty of Medicine in the Galilee, Bar Ilan University, Ramat Gan, Israel
- 16:40 **METABOLOMICS AND CANCER**
I. Tsarfaty
Dept. of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Israel
- 16:55 **ON CHROMOSOMAL ANEUPLOIDY IN CANCER AND THE FUNCTIONAL LINKAGE BETWEEN CHROMOSOMES**
R. Shamir¹, L. Ein-Dor², M. Ozery-Flato², A. Thevenin³, L. Trakhtenbrot^{4,5}, S. Izraeli^{4,6,7}
¹School of Computer Science, Tel Aviv University, ²Machine Learning and Data Mining Group, IBM Haifa Research Lab, Haifa, Israel, ³Genome Informatics, Faculty of Technology and Institute for Bioinformatics, Center for Biotechnology (CeBiTec), Bielefeld University, Germany, ⁴Sheba Cancer Research Center, ⁵Institute of Hematology, ⁶Dept. of Pediatric Hemato-Oncology, Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Tel Hashomer, ⁷Sackler School of Medicine, Tel Aviv University, Israel
- 17:05 **PLACENTA TELLS BREAST CANCER CELLS: MIGRATE AND SURVIVE, BUT ELSEWHERE!**
G. Epstein Shochet^{1,2}, S. Tartakover-Matalon^{1,2}, L. Drucker^{1,2}, M. Pomeranz², A. Fishman^{1,2}, M. Pasmanik-Chor³, M. Lishner^{1,2}
¹Sackler Faculty of Medicine, Tel Aviv University, ²Oncogenetic Laboratory, Meir Medical Center, Kfar-Saba, ³Bioinformatics Unit, Tel Aviv University, Israel

Thursday, June 20, 2013 (cont'd)

16:15-18:05 **Session VI - Everything You Always Wanted to Know about Omics and Cancer (cont'd)** Alon Hall

- 17:15 D538G ACQUIRED MUTATION OF ESTROGEN RECEPTOR (ER) ALPHA: A NOVEL MECHANISM OF ENDOCRINE RESISTANCE IN METASTATIC BREAST CANCER
K. Merenbakh-Lamin^{1,2}, N. Ben-Baruch³, A. Yehekel⁴, A. Dvir⁵, L. Soussan-Gutman⁵, D. Sarid¹, S. Rizel⁶, B. Klein⁷, T. Rubinek¹, I. Wolf^{1,2}
¹Institute of Oncology, Tel Aviv Sourasky Medical Center, ²Sackler Faculty of Medicine, Tel Aviv University, ³Kaplan Medical Center, Rehovot, ⁴The Bioinformatics Unit, Goerge S. Wise Faculty of Life Sciences, Tel Aviv University, ⁵Oncotest-Teva Pharmaceutical Industries, Petach Tikva, ⁶Rabin Medical Center, Petach Tikva, ⁷Assuta Medical Center, Tel Aviv, Israel
- 17:25 HARNESSING SYNTHETIC LETHALITY TO IDENTIFY SELECTIVE CANCER DRUG TARGETS
L. Jerby¹, A. Weinstock¹, T. Geiger², E. Ruppin^{1,2}
¹The Blavatnik School of Computer Science, ²The Sackler School of Medicine, Tel Aviv University, Israel
- 17:35 EPIGENETICS
E.N. Gal-Yam
Institute of Oncology and the Sheba Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer, Israel
- 17:50 DEEP AND QUANTITATIVE PROTEOMIC ANALYSIS OF BREAST TUMORS USING SUPER-SILAC AND HIGH RESOLUTION MASS SPECTROMETRY
Y. Pozniak¹, S. Tyanova², C. Avivi³, J. Cox², M. Mann², I. Barshack³, **T. Geiger**¹
¹The Dept. of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Israel, ²Max Planck Institute of Biochemistry, Martinsried, Germany; ³Institute of Pathology, Chaim Sheba Medical Center, Tel Hashomer, Israel
- 18:05 Break, Poster Viewing and Visit the Exhibition

Thursday, June 20, 2013 (cont'd)

18:25-19:25	Session VII - Infrastructure for Cancer Research at Tel Aviv University	Alon Hall
-------------	--	-----------

Chairs: **I.P. Witz**
Y. Skornick

18:25 **I. Tsarfaty**
Dept. of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Israel

18:40 **D. Peer**
Dept. of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Center for Nanoscience and Nanotechnology, Tel Aviv University, Israel

18:55 **M. Pasmanik-Chor**
Bioinformatics Unit, Tel Aviv University, Israel

19:10 FROM IP TO PHARMACEUTICAL PATENTS AND VALUE
S. Hirsch
Ramat, Tel Aviv University, Israel

19:25 Dinner

20:30 FUTURE DIRECTIONS OF THE CANCER BIOLOGY RESEARCH CENTER
N. Arber
The Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center, Israel

21:00 **Social Event**
Moderator: **N.Arber**

CHALLENGES AND OPPORTUNITIES IN A CHANGING SECURITY REALITY
Y. Galant - IDF

Friday, June 21, 2013

08:00-08:55

Breakfast & Meet the Expert

Parallel Session A

Alon Hall

PALESTINIANS, ISRAELIS AND CANCER

I. Al-Sadi, An-Najah National University Hospital, Nablus,
Palestinian National Authority

H. Darwish, Al-Quds University, Abu Dies, Jerusalem

S. Lolias, HRL Lab Bethlehem University and Shaare Zedek
Medical Center

I. Tsarfaty, Sackler Faculty of Medicine, Tel Aviv University, Israel

Parallel Session B

Rakefet Hall

RESEARCH FOR PHYSICIANS! CAN IT EXIST?

R. Catane

Dept. of Oncology, Chaim Sheba Medical Center,
Tel Hashomer, Israel

Parallel Session C

Narkis Hall

HOW DO I WRITE MY FIRST PAPER?

Y. Keisari

Clinical Microbiology and Immunology, Sackler School
of Medicine, Tel Aviv University, Israel

Parallel Session D

Calanit Hall

GENOMICS OF CANCER

S. Ogawa

Center for Stem Cell Biology, Institute of Medical Science,
University of Tokyo, Japan

Parallel Session E

Gal Hakahol Hall

MICROENVIRONMENT AND METASTASIS

I.P. Witz

Dept. of Cell Research and Immunology,
George S. Wise Faculty of Life Sciences,
Tel Aviv University, Israel

08:55 Technical Break

Friday, June 21, 2013 (cont'd)

09:00-10:30	Session VIII - Genomic Signature and Cancer Therapy	Alon Hall
-------------	--	-----------

Chairs: **D. Neumann**
 G. Markel

09:00 COLORECTAL CANCER
R. Geva
Dept. of Medical Oncology, Tel Aviv Sourasky Medical Center and Tel Aviv University, Israel

09:20 BREAST CANCER
E. Evron
Dept. of Oncology, Assaf Harofeh Medical Center, Zerifin, Israel

09:40 PROSTATE CANCER GENOMICS
A. Sella
Dept. of Oncology, Assaf Harofeh Medical Center, Zerifin, Israel

10:00 ERYTHROPOIETIN - THE RED HORMONE: AN ASSET OR A BURDEN?
H.S. Oster^{1,3}, N. Deshet-Unger^{2,3}, Y. Ohana^{2,3}, S. Hiram-Bab^{2,3}, D. Neumann^{2,3}, **M. Mittelman**^{1,3}
¹Dept. of Medicine, Tel Aviv Sourasky Medical Center, ²Dept. of Cell and Developmental Biology, ³Sackler Faculty of Medicine, Tel Aviv University, Israel

10:20 RAS CHAPERONS: TARGETS FOR CANCER AND IMMUNE THERAPY
Y. Kloog¹, A. Mor¹, E. Aizman¹, R. Haklai¹, G. Elad¹, J. Chapman², A. Mor³
¹Dept. of Neurobiology, Faculty of Life Sciences, ²Depts. of Physiology & Pharmacology and Neurology, Sackler Faculty of Medicine, Tel Aviv University, Israel, ³Depts. of Medicine and Pathology, New York University School of Medicine, New York, NY, USA

10:30 Panel Discussion

10:40 Break, Poster Viewing and Visit the Exhibition

Friday, June 21, 2013 (cont'd)

11:00-12:00	Session IX - Clinical Applications of Molecular Markers	Alon Hall
-------------	--	-----------

Chairs: **P. Raanani**
V. Padler-Karavani

- 11:00 TOWARDS PERSONALIZED THERAPY IN NEUROBLASTOMA
S. Ash^{1,4}, G. Feinberg-Gorenshtein^{2,4}, M. Feinmesser^{3,4}, D. Gaash^{1,2},
H. Mirsky^{1,2,4}, M. Jeison^{1,4}, N.A. Sharon¹, A. Weizman^{1,2,4}, I. Yaniv^{1,2,4},
S. Avigad^{1,2,4}
¹Pediatric Hematology Oncology, Schneider Children's Medical Center of
²Molecular Oncology, Felsenstein Medical Research Center, ³Institute of
Pathology, Rabin Medical Center, Petach Tikva, ⁴Sackler Faculty of
Medicine, Tel Aviv University, Israel
- 11:15 THE ROLE OF TSLP RECEPTOR PATHWAY IN THE DEVELOPMENT
OF ACUTE LYMPHOBLASTIC LEUKEMIA
I. Geron^{1,2,3}, N. Tal^{1,2}, N. Gershman¹, A. Nagler^{2,4}, S. Izraeli^{1,2}
¹Childhood Leukemia Research Institute, Cancer Research Center
Sheba Medical Center, Tel Hashomer, ²Sackler Faculty of Medicine,
Tel Aviv University, Israel, ³Division of Biological Sciences and Dept. of
Medicine, University of California San Diego, La Jolla, CA, USA,
⁴Division of Hematology, Bone Marrow Transplantation and Umbilical
Cord Blood Bank, Chaim Sheba Medical Center, Tel Hashomer, Israel
- 11:25 TUMOR CELL-SECRETED OSTEOPOINTIN ACTIVATES NORMAL
MAMMARY FIBROBLASTS TO ACQUIRE A CAF-LIKE PHENOTYPE
S. Yoray¹, T. Geiger², N. Erez¹
¹Dept. of Pathology, ²Dept. of Human Molecular Genetics and
Biochemistry, Sackler School of Medicine, Tel Aviv University, Israel
- 11:35 THE NEW MECHANISM OF METASTATIC MELANOMA PROGRESSION
R. Ortenberg^{1,5}, G. Galore-Haskel^{1,5}, B. Zamlin¹, I. Greenberg¹,
S. Sapoznik¹, M.J. Besser^{1,5}, E. Azizi³, E. Friedman⁴, J. Schachter¹,
G. Markel^{1,2,5}
¹Ella Institute of Melanoma, ²Talpiot Medical Leadership Program,
³Dept. of Dermatology, ⁴The Susanne Levy Gertner Oncogenetics Unit,
Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center,
Tel Hashomer, ⁵Dept. of Clinical Microbiology and Immunology,
Faculty of Medicine, Tel Aviv University, Israel
- 11:45 THE MOLECULAR PATHOGENESIS AND CLINICAL IMPLICATIONS OF
MYELOPROLIFERATIVE NEOPLASMS
M. Koren-Michowitz
Division of Hematology, Chaim Sheba Medical Center, Tel Hashomer,
Israel

Friday, June 21, 2013 (cont'd)

12:00-13:00	Session X - Stem Cells and Epithelial to Mesenchymal Transitions	Alon Hall
-------------	---	-----------

Chairs: **S. Ogawa**
 S. Izraeli

12:00 **TAKING THE STEM OUT OF PEDIATRIC CANCER**
 B. Dekel
 The Pediatric Stem Cell Research Institute & Division of Pediatric Nephrology, Edmond & Lili Safra Children's Hospital, Chaim Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Israel

12:15 **THE INFLAMMATION-EMT AXIS IN BREAST CANCER**
 T. Leibovich-Rivkin, P. Weitzenfeld, S. Lerrer, C. Katanov, Y. Lebel-Haziv, Y. Liubomirski, T. Meshel, **A. Ben-Baruch**
 Dept. of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel

12:30 **NORMAL AND MALIGNANT HEMATOPOIETIC STEM CELLS: FUNCTIONAL SCREEN FOR REGULATORS OF DNA DAMAGE RESPONSE**
 M. Milyavsky¹, O.I. Gan², M.F. Van Delft¹, A. Buzina³, T. Ketela³, L. Shenhav¹, J. Moffat³, J.E. Dick²
 ¹Dept. of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Israel, ²Ontario Institute for Cancer Research, University Health Network, ³Dept. of Molecular Genetics, University of Toronto, Toronto, ON, Canada

12:45 Panel Discussion

13:00 Lunch Break, Poster Viewing and Visit the Exhibition

13:00-14:00	Lunch & Debate	
-------------	---------------------------	--

<u>Parallel Session A</u>	Alon Hall
----------------------------------	------------------

BREAST
A. Ben-Baruch¹, **R. Catane**², **M. Papa**³
¹Dept. of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, ²Dept. of Oncology, Chaim Sheba Medical Center, Tel Hashomer, ³Dept. of Surgical Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel

<u>Parallel Session B</u>	Rakefet Hall
----------------------------------	---------------------

TISSUE BANKING
I. Barshack¹, **S. Kraus**²
¹Dept. of Pathology, Chaim Sheba Medical Center, Tel Hashomer, ²The Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center, Israel

Friday, June 21, 2013 (cont'd)

13:00-14:00

Lunch & Debate (cont'd)

Parallel Session C

Narkis Hall

COLORECTAL CANCER

R. Geva¹, D. Sidransky², I. Wolf³

¹Dept. of Medical Oncology, Tel Aviv Sourasky Medical Center and Tel Aviv University, Israel, ²Dept. of Otolaryngology and Oncology, Johns Hopkins University, Baltimore, MD, USA, ³Institute of Oncology, Tel Aviv Sourasky Medical Center, Israel

Parallel Session E

Gal Hakahol Hall

CANCER PATHOLOGY-TODAY AND
TOMORROW-MICROSCOPE OR MOLECULES?

I. Tsarfaty

Dept. of Clinical Microbiology and Immunology,
Sackler Faculty of Medicine, Tel Aviv University, Israel

14:00-15:40

Session XI - Keynote Lectures

Alon Hall

Chairs: **Y. Kloog**
R. Margalit

14:00 PROGRAMMING DNA METHYLATION IN CANCER

D. Nejman, **H. Cedar**

Dept. of Developmental Biology, The Hebrew University of Jerusalem,
Israel

14:45 INTEGRATED GENOMICS AND AVATAR MOUSE MODELS FOR
PERSONALIZED CANCER TREATMENT

D. Sidransky

Dept. of Otolaryngology and Oncology, Johns Hopkins University,
Baltimore, MD, USA

15:30 Best Poster Award Ceremony

Chairs: **P. Raanani, A. Sella, I. Tsarfaty, L. Vardimon**

19:30 Dinner

20:30 **Social Event**

Moderator: **D. Canaani**

IS THERE ANY CONTINUATION OF THE ZIONIST REVOLUTION?

A.B. Yehoshua

Saturday, June 22, 2013

- 11:00 TRENDS IN CANCER RESEARCH: PAST, PRESENT AND
FUTURE
N. Arber
The Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical
Center, Israel
- 11:00 **Safed Tour**
SAFED IN SONG AND IN POETRY - DISCOVER UNKNOWN
LAND -FROM FLAVIUS JOSEPHUS TILL TODAY
Guide - **David Amiel**

POSTERS - THURSDAY, 20.6.13

BRAIN TUMORS

Title	Board No.
<p>RAS INHIBITION BY FTS ATTENUATES BRAIN TUMORS GROWTH IN MICE BY DIRECT ANTITUMOR ACTIVITY AND ENHANCED REACTIVITY OF CYTOTOXIC LYMPHOCYTES</p> <p>E. Aizman, A. Mor, A. Levy, J. George, Y. Kloog Dept. of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel</p>	1
<p>INTRODUCING A NOVEL INTRA-CAROTID ARTERY INOCULATION METHOD: ADVANTAGES FOR STUDYING BRAIN METASTASIS</p> <p>A. Benbenishty^{1,2,3}, N. Segev-Amzaleg^{1,2}, S. Ben-Eliyahu^{1,3}, P. Blinder^{1,2}</p> <p>¹Sagol School of Neuroscience, Tel Aviv University, ²Dept. of Neurobiology, Tel Aviv University, ³School of Psychological Sciences, Tel Aviv University, Israel</p>	2
<p>MICRODIALYSIS MEASUREMENT OF INTRATUMORAL TEMOZOLOMIDE CONCENTRATION AFTER CEDIRANIB, A PAN-VEGF RECEPTOR TYROSINE KINASE INHIBITOR, IN A U87 GLIOMA MODEL</p> <p>R. Grossman^{1,7}, B. Tyler¹, M.A. Rudek², E. Kim³, P. Zadnik¹, U. Khan¹, J.O. Blakeley⁴, A.P. Pathak⁵, H. Brem^{1,3,6}</p> <p>¹Dept. of Neurosurgery, ²The Sidney Kimmel Comprehensive Cancer Center, ³Biomedical Engineering, ⁴Dept. of Neurology, ⁵Radiology, ⁶Oncology, Johns Hopkins University School of Medicine Baltimore, Maryland, USA, ⁷Dept. of Neurosurgery, Tel Aviv Sourasky Medical Center, Israel</p>	3
<p>MICROMETASTASIS REGULATION BY THE LUNG MICROENVIRONMENT IN NEUROBLASTOMA</p> <p>S. Maman^{1,2}, L. Edry-Botzer¹, O. Sagi-Assif¹, T. Meshel¹, W. Yuan², W. Lu², I.P. Witz^{1,2}</p> <p>¹Dept. of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel, ²Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA</p>	4
<p>COMPUTER-BASED IDENTIFICATION OF A NOVEL LIMK1/2 INHIBITOR THAT SYNERGIZES WITH RAS INHIBITOR TO DESTABILIZE THE ACTIN CYTOSKELETON AND TO INHIBIT CANCER AND NEUROFIBROMATOSIS CELL GROWTH</p> <p>R. Rak³, Y. Kloog³, S. Carmeli², H. Wolfson¹</p> <p>¹Blavatnik School of Computer Science, and School of Chemistry, ²Raymond and Beverly Sackler Faculty of Exact Sciences, ³Dept. of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel</p>	5

Posters - Thursday, 20.6.13 (cont'd.)

BREAST/OVARIAN CANCERS

Title	Board No.
<p>TARGETING BREAST CANCER BONE METASTASES USING POLYMER THERAPEUTICS BEARING PACLITAXEL AND ALENDRONATE K. Miller¹, A. Eldar-Boock¹, D. Polyak¹, C. Clementi², I. Barshack^{3,4}, G. Pasut², A. Amir¹, R. Satchi-Fainaro¹ ¹Dept. of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Israel, ²Dept. of Pharmaceutical Sciences, University of Padova, Italy, ³Dept. of Pathology, Sackler School of Medicine, Tel Aviv University, Israel, ⁴Dept. of Pathology, Chaim Sheba Medical Center, Tel Hashomer, Israel</p>	6
<p>COMBINED ANTICANCER THERAPY OF POLYMER CONJUGATES TO BREAST AND OVARIAN CANCER H. Baabur-Cohen, E. Markovsky, R. Satchi-Fainaro Dept. of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Israel</p>	7
<p>BREAST CARCINOMA ABLATION BY INTRATUMORAL RA-224 LOADED WIRES ENHANCES SYSTEMIC ANTI-TUMOR IMMUNITY H. Confino¹, I. Hochman¹, M. Efrati¹, M. Schmidt², I. Kelson², Y. Keisari¹ ¹Dept. of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, ²School of Physics and Astronomy, Sackler Faculty of Exact sciences, Tel Aviv University, Israel</p>	8
<p>GROWTH OF POORLY DIFFERENTIATED ENDOMETRIAL CARCINOMA IS INHIBITED BY COMBINED ACTION OF MEDROXYPROGESTERONE ACETATE AND THE RAS INHIBITOR SALIRASIB R. Faigenbaum¹, R. Haklai¹, G. Ben-Baruch², Y. Kloog¹ ¹Dept of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, ²Dept of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Israel</p>	9

Posters - Thursday, 20.6.13 (cont'd)

BREAST/OVARIAN CANCERS (cont'd)

Title	Board No.
<p>DCIS AND IDC BREAST CANCER TUMOR EVOLUTION: CHARACTERIZING THE INVASIVE POTENTIAL S. Kahana-Edwin¹, M. Dadiani¹, L. Tirosh¹, A. Pavlovsky², A. Yosepovich², Y. Cohen³, N. Epstein⁴, R. Berger⁴, I. Barshack^{2,6}, L. Carmel⁵, B. Kaufman^{1,4,6} ¹Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer, ²The Institute for Pathology, Chaim Sheba Medical Center, Tel Hashomer, ³Institutional Tissue Bank, Chaim Sheba Medical Center, Tel Hashomer, ⁴Oncology Institute, Chaim Sheba Medical Center, Tel Hashomer, ⁵Dept. of Genetics, Faculty of Science, Hebrew University, Givat Ram, Jerusalem, ⁶Sackler Faculty of Medicine, Tel Aviv University, Israel</p>	10
<p>CHEMOKINE AND CELLULAR MOTIFS REGULATING THE SECRETION OF CCL2: POTENTIAL POINTS FOR INTERVENTION IN PRO-MALIGNANCY ACTIVITIES IN BREAST CANCER Y. Lebel-Haziv¹, T. Meshel¹, A. Yeheskel², E. Mamon¹, A. Ben-Baruch¹ ¹Dept. Cell Research and Immunology and ²Bioinformatics Unit, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel</p>	11
<p>TUMOR RECURRENCE VIA THE BYSTANDER EFFECT: TUMOR-DERIVED INFLAMMATORY CYTOKINES INDUCE EMT IN NON-TRANSFORMED BREAST EPITHELIAL CELLS T. Leibovich-Rivkin, Y. Liubomirski, T. Meshel, A. Ben-Baruch Cell Research and Immunology, Tel Aviv University, Israel</p>	12
<p>THE AGING SUPPRESSOR HORMONE KLOTHO: A NOVEL TUMOR SUPPRESSOR AND REGULATOR OF ESTROGEN SIGNALING IN OVARIAN CANCER I. Lojkin, O. Schwarzman, S. Bose, B.Y. Karlan, T. Rubinek, I. Wolf Tel Aviv Sourasky Medical Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA, Sackler Faculty of Medicine, Tel Aviv University, Israel</p>	13
<p>PROTEOMIC PROFILING OF LYMPH-NODE POSITIVE AND NEGATIVE BREAST TUMORS Y. Pozniak¹, C. Avivi², I. Barshack, T. Geiger ¹Sackler Faculty of Medicine, Tel Aviv University, ²Institute of Pathology, Chaim Sheba Medical Center, Tel Hashomer, Israel</p>	14
<p>CANCER ASSOCIATED FIBROBLASTS IN MAMMARY GLAND CARCINOMA ARE HETEROGENEOUS IN PHENOTYPE AND IN ORIGIN Y. Raz^{1,2}, D. Grissaru^{1,2}, N. Erez² ¹LIS Maternity Hospital, Tel Aviv Sorasky Medical Center, affiliated to Sackler Faculty of Medicine, ²Dept. of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Israel</p>	15

Posters - Thursday, 20.6.13 (cont'd)

BREAST/OVARIAN CANCERS (cont'd)

Title	Board No.
<p>AMPK-MEDIATED REVERSAL OF THE METABOLIC SWITCH BY GLUCAGON-LIKE PEPTIDE 1: A NOVEL INTERACTION BETWEEN DIABETES AND BREAST CANCER H. Ligumsky^{1,2}, T. Rubinstein^{1,2}, T. Scherf³, A. Karasik⁴, T. Rubinek¹, I. Wolf^{1,2} ¹Institute of Oncology, Tel Aviv Sourasky Medical Center, ²Sackler Faculty of Medicine, Tel Aviv University, ³Weizmann Institute of Science, Rehovot, ⁴Endocrinology Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel</p>	16
<p>THE ROLE OF NON-PEGYLATED LIPOSOMAL DOXORUBICIN (MYOCET) IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN CANCER T. Safra¹, M. Meirovitz², H. Goldenberg³, A. Fishman⁴, A. Amit⁵, A. Neuman⁵, R. Eitan⁶, C. Koren⁶, Y. Schneider⁷, O. Rosengarten⁸, S. Keren-Rosenberg⁹ ¹Tel Aviv Sourasky Medical Center, Sackler school of Medicine, Tel Aviv University, ²Soroka Medical Center, ³Naharia Medical Center, ⁴Meir Medical Center, ⁵Rambam Medical Center, ⁶Rabin Medical Center, ⁷Ziv Medical Center, ⁸Shaare Zedek Medical Center, ⁹Lin Medical Center, Israel</p>	17
<p>THE EFFECT OF BRCA1 KNOCK-DOWN ON TELOMERE DYNAMICS AND GENOMIC INSTABILITY IN NON- MALIGNANT BREAST CELLS O. Uziel, L. Zuriano, R. Yerushalmi, E. Beery, D. Frumkin, J. Nordenberg, M. Lahav FMRC, Beilinson Hospital, Petach Tikva and Tel Aviv University, Israel</p>	18
<p>INFLAMMATORY MEDIATORS, HORMONES AND GROWTH FACTORS - A DETRIMENTAL TRIO THAT LEADS TO METASTASIS FORMATION IN BREAST CANCER P. Weitzenfeld, T. Meshel, A. Ben-Baruch Dept. of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel</p>	19
<p>DNA METHYLATION HETEROGENEITY IN BREAST CANCER TUMORS A. Zundeleovich¹, Z. Mukamel², A. Pavlovsky¹, M. Dadiani¹, S. Kahana¹, B. Kaufman¹, A. Tanay², E.N. Gal-Yam¹ ¹The Sheba Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer, ²The Faculty for Mathematics and Computer Science, Weizmann Institute, Rehovot, Israel</p>	20

Posters - Thursday, 20.6.13 (cont'd)

HEMATOLOGICAL CANCERS

Title	Board No.
<p>INTERFERING IN THE CELL CYCLE PATTERN OF HEMATOPOIETIC STEM AND EARLY PROGENITOR CELLS (HSPCS) USING TARGETED NANOMEDINE DELIVERY STRATEGY N. Ben Arie¹, D. Peer² ¹Dept. of Cell Research & Immunology, Tel Aviv University, ²The Center for Nanoscience and Nanotechnology, Tel Aviv University, Israel</p>	21
<p>GENOME-SCALE EXPRESSION AND TRANSCRIPTION FACTOR BINDING PROFILES REVEALS THERAPEUTIC TARGETS IN TRANSGENIC ERG MYELOID Y. Birger¹, L. Goldberg², M. Tijssen³, R. Hannah³, S. Kinston³, J. Schütte³, G. Schiby⁴, J. Jacob-Hirsch¹, A. Biran⁵, Y. Kloog⁵, G. Marcucci⁶, C. Bloomfield⁶, B. Göttgens³, S. Izraeli² ¹Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer, Israel, ²Cancer Research Center, Sheba Medical Center, Dept. of Human Molecular Genetics and Biochemistry, Tel Aviv University, Israel, ³Dept. of Haematology, University of Cambridge, Cambridge, UK, ⁴Dept of Pathology, Chaim Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Israel, ⁵Dept of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel, ⁶Division of Hematology and Oncology, Ohio State University, Columbus, OH, USA</p>	22
<p>BENEFITS AND RISKS OF ERYTHROPOIETIN TREATMENT IN MULTIPLE MYELOMA N. Deshet-Unger¹, S. Hiram-Bab¹, Y. Ohana-Haim¹, M. Gross¹, Y. Gabet², H.S. Oster³, M. Mittelman³, D. Neumann¹ ¹Dept. of Cell and Developmental Biology, ²Dept. of Anatomy, ³Dept. of Medicine, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel</p>	23
<p>THE ROLE OF TEL-TIF2 IN ACUTE LEUKEMIA WITH COMBINED MYELOID AND T-CELL PHENOTYPE H. Fishman^{1,2}, Y. Kirschenbaum^{1,2}, I. Ganmore^{1,2}, Y. Birger¹, S. Izraeli^{1,2} ¹Institute of Childhood Leukemia Research, Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer, ²Dept. of Human Molecular Genetics and Biochemistry, Tel Aviv University, Israel</p>	24

Posters - Thursday, 20.6.13 (cont'd)

HEMATOLOGICAL CANCERS (cont'd)

Title	Board No.
<p>HOW NOVEL MUTATIONS IN THE CYTOSOLIC REGION OF EPOR INDUCE PRIMARY FAMILIAL AND CONGENITAL POLYCYTHEMIA: CHIMERIC EGFR-EPOR AS EXPERIMENTAL TOOLS M. Gross¹, N. Ben-Califa¹, H. Hasselbalch², M.F. McMullin³, C. Bento⁴, H. Cario⁵, D. Neumann¹ ¹Dept. of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Israel, ²Dept. of Hematology, Roskilde Hospital, University of Copenhagen, Copenhagen, Denmark., ³Dept. of Haematology, Belfast City Hospital, Belfast, Ireland, ⁴Laboratório de Anemias Congénitas e Hematologia Molecular, Hospital Pediátrico de Coimbra, Coimbra, Portugal, ⁵Dept. of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany</p>	25
<p>ABERRANT MicroRNA EXPRESSION IN CHRONIC MYELOID LEUKEMIA O. Hershkovitz Rokah¹, G. Granot¹, A. Ovcharenko¹, S. Modai², M. Pasmanik-Chor³, A. Toren⁴, N. Shomron², O. Shpilberg^{1,5} ¹Felsenstein Medical Research Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah Tikva, Israel, ²Dept. of Cell and Developmental Biology, Sackler School of Medicine, Tel Aviv University, Petah Tikva, Israel, ³Bioinformatics Unit, Faculty of Life Sciences, Tel Aviv University, Petah Tikva, Israel, ⁴Dept. of Pediatric Hematology-Oncology, Safra Children's Hospital, Tel-Hashomer, Israel, ⁵Institute of Hematology, Beilinson Hospital, Petah Tikva, Sackler School of Medicine, Tel Aviv University, Israel</p>	26
<p>FARNESYLTHIOSALICYLIC ACID (SALIRASIB) INHIBITS RHEB IN TSC2-NULL CELLS: A POTENTIAL TREATMENT FOR LYMPHANGIOLEIOMYOMATOSIS V. Makovski, Y. Kloog Dept. of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel</p>	27
<p>ENHANCED ADHESION & MIGRATION AND INDUCTION OF PYK2 EXPRESSION IN K562 CELLS FOLLOWING IMATINIB EXPOSURE A. Ovcharenko¹, G. Granot¹, J. Park², O. Shpilberg^{1,3}, P. Raanani^{1,3} ¹Felsenstein Medical Research Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah Tikva, Israel, ²Massachusetts Institute of Technology, Cambridge, Massachusetts, USA, ³Institute of Hematology, Beilinson Hospital, Petah Tikva, Sackler School of Medicine, Tel Aviv University, Israel</p>	28
<p>THE ROLE OF MicroRNAs IN ACUTE MEGAKARYOCYTIC LEUKEMIA OF CHILDREN WITH DOWN SYNDROME L. Shaham^{1,2}, G. Yubin⁴, E. Greenberg^{1,3}, G. Markel^{1,3}, M. Ginzburg¹, E. Eyal¹, Y. Spector⁵, J. Taub⁴, S. Izraeli^{1,3} ¹Chaim Sheba Medical Center, Tel Hashomer, ²The Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, ³Faculty of Medicine, Tel Aviv University, ⁴Children's Hospital of Michigan, Detroit, Michigan, United States of America, ⁵Rosetta Genomics, Rehovot, Israel</p>	29

Posters - Thursday, 20.6.13 (cont'd)

HEMATOLOGICAL CANCERS (cont'd)

Title	Board No.
<p>HARNESSING NANOMEDICINE FOR THERAPEUTIC INTERVENTION IN MANTLE CELL LYMPHOMA S. Weinstein^{1,2}, R. Emmanuel^{1,2}, D. Peer^{1,2} ¹Dept. of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel, ²Center for Nanoscience and Nanotechnology, Tel Aviv University, Israel</p>	30
<p>TARGETING EIF4E TRANSLATION INITIATION FACTOR IS AN ATTRACTIVE THERAPEUTIC TARGET IN MULTIPLE MYELOMA O. Attar-Schneider^{1,3}, L. Drucker^{1,3}, V. Zismanov^{1,3}, S. Tartakover Matalon^{1,3}, M. Lishner^{1,2,3} ¹Oncogenetic Laboratory, Meir Medical Center, Kfar Saba, ²Internal Medicine Dept., Meir Medical Center, Kfar Saba, ³Sackler faculty of medicine, Tel Aviv University, Israel</p>	31
<p>MYELOMA AND BONE MARROW MESENCHYMAL STEM CELLS' CROSSTALK: EFFECT ON TRANSLATION INITIATION L. Drucker^{1,3}, V. Zismanov^{1,3}, O. Attar-Schneider^{1,3}, M. Dabbah^{1,3}, S. Tartakover Matalon^{1,3}, M. Lishner^{1,3} ¹Oncogenetic Laboratory, Meir Medical center, Kfar Saba, ²Internal Medicine Dept., Meir Medical Center, Kfar Saba, ³Sackler Faculty of Medicine, Tel Aviv University, Israel</p>	32

MELANOMAS

Title	Board No.
<p>SPECIFICITY AND FUNCTIONS OF MOLECULES ASSOCIATED WITH MELANOMA BRAIN METASTASIS S. Izraely¹, O. Sagi-Assif¹, A. Klein¹, T. Meshel¹, S. Ben-Menachem¹, G. Tsarfaty², M. Ehrlich¹, A. Zaritsky³, V.G. Prieto⁴, M. Bar-Eli⁵, W. Berger⁶, D.S.B. Hoon⁷, I.P. Witz¹ ¹Dept. of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel, ²Diagnostic & Imaging Dept., Chaim Sheba Medical Center, Tel Hashomer, Israel, ³Blavatnik School of Computer Science, Tel Aviv University, Israel, ⁴Dept. of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, ⁵Dept. of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ⁶Institute of Cancer Research, Dept. of Medicine I, Medical University Vienna, Vienna, Austria, ⁷Dept. of Molecular Oncology, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, CA,USA</p>	33
<p>CD38 DEFICIENCY ATTENUATES MELANOMA PROGRESSION E. Blacher¹, N. Geva¹, L. Mayo³, R. Stein¹ ¹Dept. of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel, ²Dept. of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel, ³Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (L.M.), ⁴Dept. of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel</p>	34

Posters - Thursday, 20.6.13 (cont'd)

MELANOMAS (cont'd)

Title	Board No.
<p>MIR-20A FUNCTIONAL ROLE AND MECHANISM IN MELANOMA R. Cohen^{1,2}, E. Greenberg^{1,2}, G. Markel^{1,2,3} ¹Ella Institute of Melanoma Research, ³Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Tel Hashomer, ²Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Israel</p>	35
<p>ADAR1 REGULATES THE RESISTANCE OF MELANOMA CELLS TO T-CELLS VIA MIR-222 AND ICAM1 G. Galore-Haskel^{1,2}, Y. Wolff-Nemlich^{1,2}, E. Greenberg^{1,2}, M. Gutman³, M.J. Besser^{1,2}, J. Schachter², G. Markel^{1,2,4} ¹Dept. of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, ²Ella Institute of Melanoma, Chaim Sheba Medical Center, Tel Hashomer, ³Dept. of General Surgery (Surgery B), Chaim Sheba Medical Center, Tel Hashomer ⁴Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Tel Hashomer, Israel</p>	36
<p>SAME CLUSTER MicroRNA -17 AND-20A DIFFERENTIAL REGULATION OF AGGRESSIVE FEATURES IN MELANOMA CELLS E. Greenberg^{1,2}, S. Hajdu¹, Y. Nemlich^{1,2}, R. Cohen^{1,2}, R. Ortenberg^{1,2}, O. Itzhaki¹, J. Jacob³, M. Besser^{1,2}, Y. Keisari², J. Schachter¹, G. Markel^{1,2} ¹Ella Institute of Melanoma, Chaim Sheba Medical Center, Tel Hashomer, ²Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, ³Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer, ⁴Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Tel Hashomer, Israel</p>	37
<p>DEEP PROTEOMIC PROFILING OF MELANOMA M. Harel¹, E. Greenberg², S. Ashkenazi², G. Markel², T. Geiger¹ ¹Dept. of Human Molecular Genetics and Biochemistry, The Sackler School of Medicine, Tel Aviv University, ²Ella Institute of Melanoma, Chaim Sheba Medical Center, Tel Hashomer, Israel</p>	38
<p>THE INTERPLAY BETWEEN BRAF MUTATION AND CEACAM1 IN MELANOMA K. Kfir^{1,2}, R. Ortenberg^{1,2}, M. Besser^{1,2}, J. Schachter¹, G. Markel^{1,2,3} ¹Ella Institute of Melanoma Research, Chaim Sheba Medical Center, Tel Hashomer, ²Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, ³Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Tel Hashomer, Israel</p>	39
<p>CHARACTERIZING THE ROLE OF THE MICROENVIRONMENT IN MELANOMA BRAIN METASTASIS A. Klein¹, O. Sagi-Assif¹, S. Izraely¹, C. Nahmias², P.O. Couraud², D.S.B. Hoon³, I.P. Witz¹, N. Erez⁴ ¹Dept. of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, ²Dept. of Cell Biology, Institute Cochin, Paris, France, ³John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, CA, USA, ⁴Dept. of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Israel</p>	40

Posters - Thursday, 20.6.13 (cont'd)

MELANOMAS (cont'd)

Title	Board No.
<p>MicroRNA -MEDIATED LOSS OF ADAR1 IN METASTATIC MELANOMA PROMOTES TUMOR GROWTH Y. Nemlich^{1,6}, E. Greenberg^{1,7}, R. Ortenberg^{1,7}, M.J. Besser^{1,7}, I. Barshack², J. Jacob-Hirsch³, E. Jacoby^{3,4}, E. Eyal³, L. Rivkin¹², V.G. Prieto⁸, N. Chakravarti⁸, L.M. Duncan¹⁰, D.M. Kallenberg¹¹, E. Galun¹², D.C. Bennett¹¹, N. Amariglio³, M. Bar-Eli⁹, J. Schachter¹, G. Rechavi^{3,6}, G. Markel^{1,5,7}</p> <p>¹Ella Institute of Melanoma, Chaim Sheba Medical Center, Tel Hashomer, Israel, ²Institute of Pathology, Chaim Sheba Medical Center, Tel Hashomer, Israel, ³Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer, Israel, ⁴Dept. of Pediatric Hemato-oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel, ⁵Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Tel Hashomer, Israel, ⁶Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Israel, ⁷Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Israel, ⁸Pathology, MD Anderson Cancer Center, Houston, Texas, USA, ⁹Cancer Biology, MD Anderson Cancer Center, Houston, Texas, USA, ¹⁰Massachusetts General Hospital Dermatopathology Unit, Boston, Massachusetts, USA, ¹¹Biomedical Science Research Centre, St. George's, University of London, London, UK, ¹²Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel</p>	41
<p>THE METASTATIC MICROENVIRONMENT. FUNCTIONAL GENOMICS OF VEMURAFENIB-RESISTANT MELANOMA CELLS I. Zubrilov¹, O. Sagi-Assif¹, S. Izraely¹, A. Klein-Goldberg¹, T. Meshel¹, S. Ben-Menachem¹, D.S.B. Hoon², I.P. Witz¹</p> <p>¹Dept. of Cell Research and Immunology, Faculty of Life Sciences, Tel Aviv University, Israel, ²John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, CA, USA</p>	42

Posters - Friday, 21.6.13

BASIC MECHANISMS

Title	Board No.
<p>UNRAVELING EXTRACELLULAR MATRIX REGULATION BY TUMOR- ASSOCIATED MACROPHAGES IN COLORECTAL TUMORS R. Afik¹, E. Zigmond², I. Sagi¹, C. Varol² ¹Dept. of Biological Regulation, The Weizmann Institute of Science, Rehovot, ²The Research Center for Digestive Tract and Liver Diseases, and Sackler Faculty of Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv University, Israel</p>	1
<p>SPECIFIC ANTIBODIES PRODUCTION FOR THE RAS ONCOGENE ISOFORMS: KRAS AND HRAS A. Angel¹, Y. Kloog¹, N. Smorodinsky² ¹Dept. of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, ²Cell Research and Immunology Dept., George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel</p>	2
<p>CYTOSKELETAL CONTROL OF c-JUN TRANSLATION IS DEPENDENT ON PHOSPHORYLATION OF eIF2α AND MEDIATED BY AN INTERNAL RIBOSOME ENTRY SITE A. Atzmon, L. Blau, M. Prizant, I. Ben-Dror, L. Vardimon Dept. of Biochemistry, George S. Wise Faculty of Life Sciences Tel Aviv University, Israel</p>	3
<p>TRIM29 IS DIFFERENTIALLY REGULATED IN NORMAL EPITHELIAL TISSUES AND DISPLAYS A BIDIRECTIONAL "SWITCH" UPON TRANSFORMATION TO THE RELATED CARCINOMAS A. Avraham¹, R. Uhlmann¹, J. Sandbank², T. Karni³, I. Pappo³, A. Sella¹, S. Soonweng Cho⁴, S. Sukumar⁴, E. Evron¹ ¹Oncology Dept., Assaf Harofeh Medical Center, Zerifin, Israel, ²Pathology Dept., Assaf Harofeh Medical Center, Zerifin, Israel, ³Surgery Dept., Assaf Harofeh Medical Center, Zerifin, Israel, ⁴Oncology Dept., Johns Hopkins University, School of Medicine, Baltimore, MD, USA</p>	4
<p>THE MANY FACES OF MIMP/MTCH2, A MITOCHONDRIAL CARRIER HOMOLOGUE INVOLVED IN TUMORIGENICITY INHIBITION AND FAT ACCUMULATION Y. Bar-Lev¹, O. Cohen-Neeman¹, R. Leibowitz-Amit², G. Stein³, G.M. Yerushalmi⁴, S. Moshitch-Moshkovitz², I. Tsarfaty¹ ¹Dept. of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, ²Sheba Cancer Research Center, Chaim Sheba Medical Centre, Tel Hashomer, ³Dept. of Internal Medicine "B", Beilinson Hospital, Rabin Medical Center, Petach Tikva, ⁴Gynecology Dept., Chaim Sheba Medical Center, Tel Hashomer, Israel</p>	5

Posters - Friday, 21.6.13 (cont'd)

BASIC MECHANISMS (cont'd)

Title	Board No.
<p>STIL, A PROTEIN OVEREXPRESSED IN MULTIPLE CANCERS AND MUTATED IN PRIMARY MICROCEPHALY, IS REQUIRED FOR PRIMARY CILIA ORGANELLE FORMATION AND FOR CILIA-MEDIATED HEDGEHOG SIGNALING</p> <p>A. David^{1,2}, J. Vulprecht³, A. Castiel^{1,2}, R. Ohana², R. Ashery-Padan², D. Atias¹, T. Golan¹, A. Krämer³, S. Izraeli^{1,2}</p> <p>¹Sheba Cancer Research Center and the Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Tel Hashomer, Israel, ²Sackler Faculty of Medicine, Tel Aviv University, Israel, ³Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Dept. of Internal Medicine V, University of Heidelberg, Germany</p>	6
<p>MET CROSS TALK WITH OTHER RTK NOT THROUGH HIS CLASSICAL DOCKING SITE INDUCES CELL MOTILITY AND INVASION - A NOVEL METASTASIS MOLECULAR MECHANISM</p> <p>T. Diamant-Levi, I. Tsarfaty</p> <p>Dept. of Microbiology and Clinical Immunology, Sackler Faculty of Medicine, Tel Aviv University, Israel</p>	7
<p>DIFFERENCES IN DNA DAMAGE AND REPAIR MECHANISMS AFFECT THE SENSITIVITY OF SOLID TUMORS TO ALPHA RADIATION</p> <p>R. Etzyoni¹, M. Efrati¹, M. Schmidt², I. Kelson², Y. Keisari¹</p> <p>¹Dept. of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, ²School of Physics and Astronomy, Sackler Faculty of Exact sciences, Tel Aviv University, Israel</p>	8
<p>ALTERNATIVE SPLICING REGULATION AT THE SINGLE CELL LEVEL</p> <p>L. Faigenbloom^{*1}, N. Rubinstein^{*2}, I. Mayrose², Y. Kloog¹, T. Pupko², R. Stein¹</p> <p>¹Dept. of Neurobiology, Tel Aviv University, ²Dept. of Cell Research and Immunology, Tel Aviv University, Israel</p> <p>*Equal contribution</p>	9
<p>SOMATOSTATIN RECEPTOR SUBTYPE EXPRESSION IN HUMAN PANCREATIC TUMORS</p> <p>A. Hesin^{1,2}, I. Barshack³, G. Kostenich⁴, A. Orenshtein⁴, I. Wolf^{1,2}, M. Oron-Herman⁴</p> <p>¹Institute of Oncology, Tel Aviv Sourasky Medical Center, ²Sackler Faculty of Medicine, Tel Aviv University, ³Institute of Pathology, Chaim Sheba Medical Center, Tel Hashomer, ⁴Advanced Technology Center, Chaim Sheba Medical Center, Tel Hashomer, Israel</p>	10

Posters - Friday, 21.6.13 (cont'd)

BASIC MECHANISMS (cont'd)

Title	Board No.
<p>ERYTHROPOIETIN RECEPTOR IN ENDOPLASMATIC RETICULUM STRESS - MAINTENANCE OF SURFACE LEVELS DESPITE REDUCTION OF INTRACELLULAR RECEPTOR LEVELS D. Inbar¹, O. Ravid¹, C. Koumenis², N. Ben-Califa¹, F. Grunert³, J. Thompson³, D. Neumann¹ ¹Dept. of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Israel, ²Dept. of Radiation Oncology, Perelman School of Medicine; University of Pennsylvania School of Medicine, Philadelphia, PA USA, ³Aldevron Freiburg GmbH, Germany</p>	11
<p>HEPATOCTE-DERIVED EXTRACELLULAR MATRIX INDUCES MESENCHYMAL TO EPITHELIAL TRANSITION (MET) IN METASTATIC COLORECTAL CANCER CELLS A. Kaganovich, I. Zvibel, C. Varol, Z. Halpern, E.M. Santo, R. Kariv The Research Center for Digestive Tract and Liver Diseases, Tel Aviv Sourasky Medical Center, Israel</p>	12
<p>UPREGULATION OF THE PROTO-ONCOGENE C-JUN BY E-CADHERIN MEDIATED SIGNALING PATHWAY R. Knirsh¹, I. Ben-Dror¹, B. Spangler², G.D. Matthews¹, S. Kuphal², A.K. Bosserhoff², L. Vardimon¹ ¹Dept. of Biochemistry, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel, ²Institute of Pathology, University of Regensburg, Franz-Josef-Strauss- Regensburg, Germany</p>	13
<p>GENETIC VARIANTS OF THE CD24 GENE AND THEIR ROLE IN THE SUSCEPTIBILITY TO INFLAMMATORY BOWEL DISEASE V. Lisiansky¹, I. Naumov¹, D. Kazanov¹, O. Toledano¹, M. Leshno¹, D. Avivi¹, I. Dotan², M. Moshkowitz¹, N. Arber¹, S. Kraus¹ ¹The Integrated Cancer Prevention Center, ²The Research Center for Digestive Tract and Liver Diseases, Tel Aviv Sourasky Medical Center, ³The Sackler Faculty of Medicine, Tel Aviv University, Israel</p>	14
<p>A CD24 POLYMORPHISM IS ASSOCIATED WITH EARLY ONSET AND HIGH RATE OF RECURRENCE AMONG COLORECTAL CANCER PATIENTS I. Naboishchikov¹, E.Liberman¹, I.Naumov¹, V. Lisiansky¹, R. Geva², J. Greenberg², E. Shmueli², D. Kazanov¹, M. Leshno³, M. David¹, D. Sion¹, N. Arber¹, S. Kraus ¹The Integrated Cancer Prevention Center, ²Dept. of Oncology, Tel Aviv Sourasky Medical Center, ³Sackler School of Medicine, Tel Aviv University, Israel</p>	15

Posters - Friday, 21.6.13 (cont'd)

BASIC MECHANISMS (cont'd)

Title	Board No.
<p>ERYTHROPOIETIN INDUCES TRANSLOCATION OF THE GLUCOCORTICOID RECEPTOR TO THE NUCLEUS, IN THE ABSENCE OF GLUCOCORTICOID RECEPTOR AGONISTS Y. Ohana Haim¹, N. Ben-Califa¹, M.C. Souroujon³, M. Mittelman^{2,4}, D. Neumann¹</p> <p>¹Dept. of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, ²Dept. of Medicine A, Tel Aviv Sourasky Medical Center, ³Dept. of Natural Sciences, The Open University of Israel, University Rd, Raanana, ⁴Sackler Faculty of Medicine, Tel Aviv University, Israel</p>	16
<p>A GENETIC VARIANT OF 5-HYDROXYTRYPTAMINE RECEPTOR 3C (HTR3C): A NOVEL LINK TO CHEMOTHERAPY-INDUCED SIDE EFFECTS. G. Har-Zahav³, D. Pud⁵, Y. Leitman⁴, Z. Symon⁶, T. Rubinek¹, I. Wolf^{1,2}</p> <p>¹Oncology Dept., Tel Aviv Sourasky Medical Center, ²Sackler School of Medicine, Tel Aviv University, ³Surgery B, Chaim Sheba Medical Center, Tel Hashomer, ⁴Oncogenetic Unit, Chaim Sheba Medical Center, Tel Hashomer, ⁵School of Medicine, University of Haifa, Haifa, ⁶Oncology Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel</p>	17
<p>APC I1307K POLYMORPHISM AS A PREDICTIVE FACTOR FOR COLORECTAL NEOPLASIA RECURRENCE B. Boursi^{1,2,4}, T. Sella², E. Liberman^{1,4}, R. Geva^{3,4}, E. Shacham-Shmueli^{2,4}, D. Kazanov¹, S. Kraus¹, N. Arber^{1,4}</p> <p>¹The Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center; ²Dept. of Medical Oncology, Chaim Sheba Medical Center, Tel Hashomer, ³Dept. of Medical Oncology, Tel Aviv Sourasky Medical Center and ⁴Tel Aviv University, Israel BB and TS equally contributed to the study and manuscript</p>	18
<p>NEUREGULIN PROMOTES INCOMPLETE AUTOPHAGY OF PROSTATE CANCER CELLS THAT IS INDEPENDENT OF MTOR PATHWAY INHIBITION E. Schmukler¹, B. Shai², M. Ehrlich², R. Pinkas-Kramarski¹</p> <p>Dept. of Neurobiology¹, Dept. of Cell Research and Immunology², George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel</p>	19
<p>INHIBITION OF THE ONCOGENIC SYNERGISM BETWEEN ERBB1, RAS AND NUCLEOLIN S. Schokoroy, R. Pinkas Kramarski</p> <p>Dept. of Neurobiology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel</p>	20
<p>CAN STRESS HORMONES TRANSFORM DORMANT TUMORS TO FAST-GROWING TUMORS? L. Shaashua¹, S. Ferber², R. Satchi-Fainaro², S. Ben-Eliyahu¹</p> <p>¹Neuroimmunology Research Unit, Sagol School of Neuroscience, School of Psychological Sciences, Tel Aviv University, ²Dept. of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Israel</p>	21

Posters - Friday, 21.6.13 (cont'd)

CANCER THERAPY

Title	Board No.
<p>A NOVEL METHOD OF DETERMINING NANO SCALE CELLULAR FLUCTUATION I. Barnea, N.T. Shaked The Biomedical Optical Microscopy, Nanoscopy and Interferometry Research Group, Dept. of Biomedical Engineering, Tel Aviv University, Israel</p>	22
<p>OVERCOMING PACLITAXEL RESISTANCE WITH ANTI-ANGIOGENIC AND ANTICANCER RGD-BEARING NANOMEDICINE A. Eldar-Boock¹, D. Ben-Shushan¹, J. Sanchis², R. Lupu³, M.J. Vicent², R. Satchi-Fainaro¹ ¹Dept. of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Israel, ²Centro de Investigación Príncipe Felipe, Medicinal Chemistry Unit, Polymer Therapeutics Laboratory, Valencia, Spain, ³Mayo Clinic, Mayo Medical Laboratories, Rochester, MN, USA</p>	23
<p>NON-INVASIVE INTRAVITAL MONITORING OF DRUG RELEASE FROM NOVEL POLYMERIC THERANOSTIC NANOMEDICINES R. Blau, R. Satchi-Fainaro Dept. of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Israel</p>	24
<p>HIF-1A AND B-TRCP INTERACTION IN CANCER CELLS M. Cohen, M. Golan, N.J. Mabeesh Prostate Cancer Research Laboratory, Dept. of Urology, Tel Aviv Sourasky Medical Center, Israel</p>	25
<p>PROSPECTIVE PILOT CLINICAL TRIAL OF "THE WORK" MEDITATION FOR SURVIVORS OF BREAST CANCER S. Lev-Ari¹, S. Zilcha-Mano², L. Rivo³, R. Geva³, I. Ron³, S. Conti³ ¹Center of Complementary and Integrative Medicine, Institute of Oncology, Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, ²School of Psychology, Interdisciplinary Center (IDC), Herzliya, ³Institute of Oncology, Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Israel</p>	26
<p>MAPPING MODIFIERS OF THE APC GENE IN INTESTINAL CANCER DEVELOPMENT USING THE COLLABORATIVE CROSS MOUSE REFERENCE POPULATION A. Dorman¹, R. Mott², I. Tomlinson², F.A. Iraqi¹ ¹Dept. of Clinical Microbiology & Immunology, Sackler Faculty of Medicine, Tel Aviv University, Israel, ²Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK</p>	27
<p>EFFECT OF PROSTACAD AND MODIFIED CITRUS PECTIN ON SURVIVAL OF PROSTATE CANCER CELLS L. Edry-Botzer, A. Vexler, S. Conti, S. Katzburg, N. Honig, N. Shtraus, G. Earon, I. Ron, S. Lev-Ari Laboratory of Herbal Medicine and Cancer Research, Tel Aviv Sourasky Medical Center, Israel</p>	28

Posters - Friday, 21.6.13 (cont'd)

CANCER THERAPY (cont'd)

Title	Board No.
<p>REGRESSING THE ANGIOGENIC SWITCH OF CALCIFIED NEOPLASMS USING COMBINED POLYMER THERAPEUTICS E. Segal¹, Y. Epshtein¹, P. Huaizhong², P. Ofek¹, R. Shreberk¹, T. Udagawa³, P. Kopečková², J. Kopeček², R. Satchi-Fainaro¹ ¹Dept. of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Israel, ²Dept. of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah, USA, ³Vascular Biology Program and Dept. of Surgery, Karp Family Research Laboratories, Children's Hospital Boston and Harvard Medical School, Boston, USA</p>	29
<p>ADOPTIVE TRANSFER OF TUMOR INFILTRATING LYMPHOCYTES IN METASTATIC MELANOMA PATIENTS: INTENT-TO-TREAT ANALYSIS AND EFFICACY AFTER FAILURE TO PRIOR IMMUNOTHERAPIES M.J. Besser^{1,2}, R. Shapira-Frommer³, O. Itzhaki², A.J. Treves⁴, D.B. Zippel⁵, D. Levy², A. Kubi², N. Shoshani², D. Zikich², Y. Ohayon², B. Shalmon⁶, G. Markel^{1,2}, R. Yerushalmi⁷, S. Apter⁸, A. Ben-Nun⁹, E. Ben-Ami³, A. Shimoni⁷, A. Nagler⁷, J. Schachter² ¹Dept. of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, ²Ella Institute, Chaim Sheba Medical Center, Tel Hashomer, ³Oncology Division, Chaim Sheba Medical Center, Tel Hashomer, ⁴Sheba Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer, ⁵Dept. of Surgical Oncology, Chaim Sheba Medical Center, Tel Hashomer, ⁶Dept. of Pathology, Chaim Sheba Medical Center, Tel Hashomer, ⁷Dept. of Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, ⁸Dept. of Imaging, Chaim Sheba Medical Center, Tel Hashomer, ⁹Dept. of Thoracic Surgery, Chaim Sheba Medical Center, Tel Hashomer, Israel</p>	30
<p>TARGETING NCAM-EXPRESSING TUMORS WITH POLYMER THERAPEUTICS E. Markovsky, R. Satchi-Fainaro Dept. of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Israel</p>	31
<p>A NOVEL STRUCTURAL MODEL OF THE HORMONE KLOTHO AND THE DISCOVERY OF A UNIQUE DOMAIN WITH POTENT ANTI-TUMORAL ACTIVITY K. Merenbakh-Lamin^{1,2}, H. Ligumsky^{1,2}, S. Shahmoon^{1,2}, T. Rubinek¹, I. Wolf^{1,2} ¹Institute of Oncology, Tel Aviv Sourasky Medical Center, ²Sackler Faculty of Medicine, Tel Aviv University, Israel</p>	32
<p>MET REGULATION OF TUMOR METABOLISM, BLOOD FLOW AND METASTASIS S. Natan¹, G. Tsarfay², M. Shaharabany¹, J. Horev¹, I. Tsarfay¹ ¹Sackler School of Medicine, Tel Aviv University, ²Dept. of Radiology, Chaim Sheba Medical Center, Tel Hashomer, Israel</p>	33

Posters - Friday, 21.6.13 (cont'd)

CANCER THERAPY (cont'd)

Title	Board No.
<p>POLYMER-BASED NANOMEDICINES FOR TARGETED-DOXORUBICIN DELIVERY TO TUMOR AND ITS STROMA D. Polyak¹, C. Ryppa², F. Kratz², B. Polyak³, R. Satchi-Fainaro¹ ¹Dept. of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Israel, ²Tumor Biology Center, Freiburg, Germany, ³Dept. of Surgery, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA</p>	34
<p>MOLECULAR IMAGING OF TUMORS AND METASTASES USING CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) MRI M. Rivlin¹, J. Horev², I. Tsarfaty², G. Navon¹ ¹School of Chemistry, Tel Aviv University, Israel, ²Dept. of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Israel</p>	35
<p>TRACKING DOWN METASTATIC MELANOMA BY ADOPTIVELY TRANSFERRED ENGINEERED T CELLS S. Sapoznik¹, S. Kozlovski^{1,2}, M. Besser^{1,2}, J. Schachter¹, C. Cohen³, G. Markel^{1,2,4} ¹The Ella Institute for Melanoma Research and Treatment, Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer, ²Clinical Microbiology and Immunology, Sackler School of Medicine of the Tel Aviv University, ³Life Science Faculty, Bar Ilan University, ⁴Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Tel Hashomer, Israel</p>	36
<p>FOLATE RECEPTOR-TARGETED DRUG DELIVERY SYSTEMS OF DOXORUBICIN FOR THE TREATMENT OF CANCER A. Scomparin¹, A. Eldar-Boock¹, S. Ferber¹, G. Tiram¹, H. Shmeeda², A. Gabizon², S. Salmaso³, P. Caliceti³, N. Landa-Rouben⁴, J. Leor⁴, R. Satchi-Fainaro¹ ¹Dept. of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, ²Dept. of Oncology, Shaare Zedek Medical Center and Hebrew University-School of Medicine, Jerusalem, ³Dept. of Pharmaceutical Sciences, University of Padova, Padova, Italy, ⁴Neufeld Cardiac Research Institute, Chaim Sheba Medical Center, Tel Hashomer, Tel Aviv University, Israel</p>	37
<p>FROM MURINE TO HUMANIZED, BIG AND SMALL, UNARMED AND CONJUGATED: NOVEL AND PROMISING BIOLOGICAL TREATMENT TOOLS FOR CD24-EXPRESSING MALIGNANCIES S. Shapira¹, D. Kazanov¹, I. Benhar³, N. Arber¹, S. Kraus¹ ¹The Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center, ²The Sackler Faculty of Medicine, ³Dept of Molecular Microbiology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel</p>	38

Posters - Friday, 21.6.13 (cont'd)

CANCER THERAPY (cont'd)

Title	Board No.
<p>SELECTIVE ERADICATION OF CANCER CELLS BY ADENOVIRUS-BASED DELIVERY OF CYTOTOXIC AGENTS: AN ALTERNATIVE METHOD FOR TARGETING PANCREATIC CANCER</p> <p>S. Shapira¹, D. Kazanov¹, I. Naboishchikov¹, N. Arber¹, S. Kraus¹</p> <p>¹Laboratory of Molecular Biology, The Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center, ²The Sackler Faculty of Medicine, Tel Aviv University, Israel</p>	39
<p>OPTIMIZATION OF ALLOGENEIC NK CELLS FOR ADOPTIVE TRANSFER THERAPY IN SOLID TUMOR PATIENTS</p> <p>M.J. Besser^{1,2}, T. Shoham³, O. Harari-Steinberg^{1,4}, N. Zabari^{1,2}, R. Ortenberg^{1,2}, A. Kubi¹, N. Shoshani¹, A. Yakirevitch⁵, A. Nagler⁶, R. Loewenthal⁷, J. Schachter¹, G. Markel^{1,2,8}</p> <p>¹Ella Institute of Melanoma, Chaim Sheba Medical Center, Tel Hashomer, ²Dept. of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, ³GreenOnyx, ⁴Pediatric Stem Cell Research Institute, Chaim Sheba Medical Center, Tel Hashomer, ⁵Dept. of Otolaryngology and Head and Neck Surgery, Chaim Sheba Medical Center, Tel Hashomer, ⁶Division of Hematology, Chaim Sheba Medical Center, Tel Hashomer, ⁷Tissue Typing Laboratory, Chaim Sheba Medical Center, Tel Hashomer, ⁸Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer, Israel</p>	40
<p>THE ELECTRICAL PARAMETERS REQUIRED FOR THE ERADICATION OF PRIMARY SOLID TUMORS BY ELECTRIC BASED-ABLATION</p> <p>I. Hochman^{1,2}, H. Confino², M. Efrati², J. Tikochkiy², R. Korenstein¹, Y. Keisari²</p> <p>¹Depts. of Physiology & Pharmacology and, ²Depts. of Clinical Microbiology & Immunology, Sackler Faculty of Medicine, Tel Aviv University, Israel</p>	41
<p>IMPACT OF KRAS MUTATIONAL STATUS ON CLINICAL OUTCOMES IN PATIENTS RECEIVING CAPECITABINE BASED CHEMOTHERAPY</p> <p>N. Yarom^{1,2}, G. Gresham^{3,4}, N. Boeme^{3,4}, D. Jonker^{3,4}</p> <p>¹Oncology Dept. Assaf Harofeh Medical Center, Zerifin, ²Sackler Medical School, Tel Aviv University, Israel, ³Medical Oncology in the Ottawa Hospital, ON, Canada, ⁴The University of Ottawa, ON, Canada</p>	42
<p>ER HOMEOSTASIS AND MOTILITY OF NSCLC CELL LINES CAN BE THERAPEUTICALLY TARGETED WITH COMBINED HSP90 AND HDAC INHIBITORS</p> <p>V. Zismanov¹, L. Drucker², M. Gottfried³</p> <p>¹Lung Cancer Research Laboratory, Meir Medical Center, Kfar-Saba, ²Oncogenetic Laboratory, Meir Medical Center, Kfar-Saba, ³Oncology Dept., Lung Cancer Unit, Meir Medical Center, Kfar-Saba, ⁴Sackler Faculty of Medicine, Tel Aviv University, Israel</p>	43

Posters - Friday, 21.6.13 (cont'd)

CANCER THERAPY (cont'd)

Title	Board No.
<p>BONE MARROW MESENCHYMAL STEM CELLS DELETERIOUSLY AFFECT LUNG CANCER CELL LINES V. Zismanov¹, L. Drucker², M. Gottfried³ ¹Lung Cancer Research Laboratory, Meir Medical Center, Kfar Saba, ²Oncogenetic laboratory, Meir Medical Center, Kfar Saba, ³Lung Cancer Unit, Oncology Dept., Meir Medical Center, Kfar Saba, Israel</p>	44
<p>C248T POLYMORPHISM AND OBESITY IN HUMANS N. Shemesh, A. Leshno, S. Shapira, B. Schwartz , I. Naboishchikov , S. Kraus, N. Arber Integrated Cancer Prevention Center, Tel Aviv Medical Center, Tel Aviv University, Israel</p>	45